Hints and tips:
...Matthew Beesley, chief executive of Jupiter Asset Management, agreed with the direction of travel but sounded a note of caution....
...Plus, on Friday, S&P will review the UK’s credit rating of AA (currently with a negative outlook) as will Moody’s. Another Friday that is unlikely to be quiet for the British press....
...TA Associates backed a management buyout at Jupiter from Commerzbank in 2007 and listed the business three years later....
...“Frothy is not the word I associate with the UK market,” observes Laura Foll, a fund manager at Janus Henderson....
...Our last published fair value of 440p (29% upside) is equivalent to a P/TNAV multiple of 0.79x....
...image, as well as performance,” says Pelham Smithers Associates....
...“There is a growing minority of funds that is moving towards paying for research from their P&L because that is best practice,” he said. “Our view is ultimately: pay for this stuff yourself....
...The Boston private equity group has a reputation for investing in asset managers, including Jupiter Fund Management before it listed. I’m 56. In terms of age I’ve got a long runway....
...Mr Lo cites UBS’s recently launched $470m oncology fund as a real-life example of portfolio theory....
...Mr Monaghan joins from S&P were he was associate director of fund research....
...Andrew Bogan, a private fund manager at Bogan Associates, says: “There are a lot of reasons, including the rash of IPOs that have been priced on promise rather than profits, to be cautious of where the biotech...
...Ms McMinn covers mid and large cap biotechnology companies with a focus on HCV and hematology/oncology drug development....
...Jupiter Fund Management led the mid-cap risers after Credit Suisse started coverage with a 290p price target....
...Shares in Aberdeen Asset Management, which has about £170bn under management, much of it in fixed income, is on a p/e rating of just less than 10....
International Edition